ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

JORGE ANGLERO ALFARO M.D.

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,946Medicare Part D Prescriptions Filled, Including Refills

Rank: 233 out of 551

$296K Total Retail Price of All Prescriptions

Rank: 212 out of 551

311 Patients Receiving at Least One Drug in Part D
72%Patients 65 Years and Older
2% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Puerto Rico
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 311 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 5,563 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$37 was the average price of a prescription from this provider, compared to $35 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 24.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Puerto Rico
SIMVASTATIN 544 422 1 1
OMEPRAZOLE 353 237 2 7
RANITIDINE HCL 319 211 3 8
METFORMIN HCL 271 179 4 2
LEVOTHYROXINE SODIUM 259 190 5 9
LOSARTAN POTASSIUM 238 162 6 6
CARVEDILOL 217 152 7 22
LOSARTAN-HYDROCHLOROTHIAZIDE 215 141 8 10
AMLODIPINE BESYLATE 164 121 9 4
GABAPENTIN 141 87 10 3
LISINOPRIL 140 104 11 14
ISOSORBIDE MONONITRATE ER 122 81 12 21
ATENOLOL 121 92 13 12
SYNTHROID 116 59 14 11
INSULIN SYRINGE 116 58 14 41
METOPROLOL SUCCINATE 111 68 16 23
FUROSEMIDE 103 87 17 13
NABUMETONE 102 46 18 37
GLIMEPIRIDE 94 70 19 16
DOXAZOSIN MESYLATE 87 75 20 25
FLUTICASONE PROPIONATE 84 56 21 66
ENALAPRIL MALEATE 84 63 21 5
FENOFIBRATE 81 58 23 34
GLIPIZIDE ER 78 55 24 85
PRAVASTATIN SODIUM 78 76 24 24
TRAMADOL HCL 77 61 26 32
AMLODIPINE BESYLATE-BENAZEPRIL 77 66 26 42
ETODOLAC 72 30 28 95
CLOPIDOGREL 70 69 29 30
LEVOXYL 69 61 30 40
DIGOXIN 67 64 31 44
COUMADIN 66 50 32 88
HUMULIN 70-30 65 38 33 35
NOVOLIN 70-30 64 30 34 172
PANTOPRAZOLE SODIUM 57 37 35 36
MELOXICAM 57 44 35 90
PLAVIX 57 37 35 33
SPIRONOLACTONE 56 50 38 79
QUINAPRIL HCL 55 38 39 104
TAMSULOSIN HCL 55 53 39 38
TRAMADOL HCL-ACETAMINOPHEN 55 43 39 18
BACLOFEN 54 29 42 123
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 27, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.